Company profile: CellProthera
1.1 - Company Overview
Company description
- Provider of autologous CD34+ stem cell therapies and expansion tools: ProtheraCytes® to regenerate damaged tissues, particularly cardiac tissue, after acute myocardial infarction; StemXpand®, an automated device for in vitro CD34+ expansion ensuring consistent quality; and StemPack®, a single-use kit used with StemXpand® for production and expansion.
Products and services
- ProtheraCytes®: Autologous cell therapy regenerating damaged, particularly cardiac, tissue after AMI using patient peripheral-blood CD34+ cells, with proof-of-principle outcomes showing excellent safety and outstanding clinical benefits
- StemPack®: Single-use kit used with StemXpand® for producing and expanding CD34+ stem cells in conjunction with the device’s operations
- StemXpand®: Automated device engineered for in vitro expansion of CD34+ stem cells, ensuring consistent quality across multiple production sites.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CellProthera
PeproMene Bio
HQ: United States
Website
- Description: Provider of BAFFR-targeted immunotherapies: BAFFR CAR-T cells for B cell malignancies and autoimmune diseases; BAFFR BiTE T cell engagers targeting CD3 and BAFF-R, showing in vitro and in vivo tumor efficacy; and allogeneic BAFFR CAR NK cells offering a potential off-the-shelf treatment option. A virtual, privately funded biotech company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PeproMene Bio company profile →
Outpace Bio
HQ: United States
Website
- Description: Provider of innovative cell therapies designed to enhance cancer treatment efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Outpace Bio company profile →
BioXyTran
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting stroke, ischemia, and COVID-19 complications. Pipeline includes BXT-25 to deliver oxygen to brain tissue during and after ischemic stroke; ProLectin-M (chewable) and ProLectin-I (IV) for mild to severe COVID-19; ProLectin-A for COVID-19-related ARDS; ProLectin-F for ventilator-induced lung fibrosis; and a galectin antagonist to reduce viral load and modulate immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioXyTran company profile →
DiscGenics
HQ: United States
Website
- Description: Provider of regenerative cell therapy for chronic back pain, offering IDCT (rebonuputemcel), an injectable therapy using proprietary Discogenic Cells to treat mild to moderate degenerative disc disease. Discogenic Cells are biomedically engineered progenitor cells derived from human intervertebral disc tissue, designed to address the environment of a degenerated disc.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DiscGenics company profile →
Angioblast
HQ: United States
Website
- Description: Provider of biotechnology therapeutic products targeting cardiovascular diseases, developing and commercializing adult stem cell therapies, protein therapeutics, gene silencing solutions, small molecule peptides and antibodies, cytokines and antigen-receptor inhibitors, DNAzymes, and MPC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Angioblast company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CellProthera
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CellProthera
2.2 - Growth funds investing in similar companies to CellProthera
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CellProthera
4.2 - Public trading comparable groups for CellProthera
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →